{"id":3810,"date":"2018-01-31T20:31:52","date_gmt":"2018-02-01T01:31:52","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3810"},"modified":"2018-02-07T15:42:44","modified_gmt":"2018-02-07T20:42:44","slug":"evolus-inc-ipo-preview-eols","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/evolus-inc-ipo-preview-eols\/","title":{"rendered":"Evolus, Inc. #IPO Preview ($EOLS)"},"content":{"rendered":"

\"Evolus\"<\/a><\/p>\n

Company: Evolus, Inc.<\/strong>
\nSymbol: EOLS
\nDescription: They are a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments.
\nShares: 5 million
\nPrice Range: $12.00-$14.00
\nTrade Date: 2\/8
\nUnderwriter(s): Cantor, Mizuho Securities
\nCo-Manager: SunTrust Robinson Humphrey, JMP Securities
\nFiled: 1-29-17
\n<\/a><\/p>\n

Link to S-1\/A Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>: They focus on the self-pay aesthetic market and our first product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. We believe we will offer physicians and patients a compelling value proposition with DWP-450. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States.<\/p>\n

Ownership:\u00a0<\/strong>In a series of related transactions in 2013, SCH acquired all of their\u00a0outstanding equity in exchange for\u00a0membership interests in SCH. In 2014, SCH contributed their\u00a0equity that it had acquired in 2013 to ALPHAEON.\u00a0As a result of these transactions, Evolus\u00a0became a wholly-owned subsidiary of ALPHAEON.\u00a0Immediately following the completion of this offering, ALPHAEON will own\u00a078.8%\u00a0of their\u00a0outstanding shares of common stock (or approximately\u00a076.4%\u00a0of our common stock, if the underwriters exercise in full their option to purchase additional shares of our common stock in this offering), and as a result, ALPHAEON will continue to have significant control of their\u00a0business.<\/p>\n

License:\u00a0<\/strong>On September 30, 2013, they\u00a0entered into the Daewoong Agreement pursuant to which Daewoong agreed to manufacture and supply EOLS\u00a0with DWP-450 and granted them\u00a0an exclusive license to develop, distribute, market and sell the product in the covered territories. Daewoong also granted EOLS\u00a0a non-exclusive license to do the same in Japan. They\u00a0have the option, subject to certain payment conditions, to expand the permitted use of the product beyond aesthetic indications and into therapeutic indications, the latter of\u00a0which they\u00a0have assigned to and are currently holding in trust for ALPHAEON. Under the Daewoong Agreement, they\u00a0are required to make certain minimum annual purchases upon commercialization in order to maintain the exclusivity of the license.<\/p>\n

Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique’s service.<\/p>\n

Indicate with confidence,\u00a0<\/b>SUBSCRIBE<\/b><\/a>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Company: Evolus, Inc. Symbol: EOLS Description: They are a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. Shares: 5 million Price Range: $12.00-$14.00 Trade Date: 2\/8 Underwriter(s): Cantor, Mizuho Securities Co-Manager: SunTrust Robinson Humphrey, JMP Securities Filed: 1-29-17 Link to S-1\/A Prospectus Link to Retail[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1461],"class_list":["post-3810","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-eols"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3810"}],"version-history":[{"count":3,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3810\/revisions"}],"predecessor-version":[{"id":3883,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3810\/revisions\/3883"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}